Perioperative oncological treatment is currently the gold standard approach in Europe for Advanced Gastric Cancer patients. Unfortunately, patients dropping out due to worsening conditions has been frequently observed, but these data are seldomly considered and reported. To analyze frequency and propose solutions to support these patients, we reconsidered our results from the GASTRODOC randomized trial performed by [blinded for reviewers] and GIRCG on 91 patients. Thirty-four patients (37.4%) suspended chemotherapy and five (5.4%) did not reach surgery. Ten patients (11%) presented unacceptable toxicity related to gastrointestinal symptoms, six ended the treatment for investigator decision and six for progression, five patients withdrew their consent, five patients were excluded because of surgical complications and long hospitalization, and two patients died. Even though not significant, survival rates for patients who interrupted treatment in the whole trial were lower (5-year OS completed 64.6 vs. interrupted 41.8 p 0.07). Promptness in giving patient support for gastrointestinal symptoms, careful evaluation of anemia and patient nutritional status, and psychological programs from the beginning of the oncologic treatment may improve the final results.

Frail patients dropping out of neoadjuvant treatment: what should we do? / Morgagni, Paolo; Monti, Manlio; Solaini, Leonardo; Foca, Flavia; Ercolani, Giorgio. - In: UPDATES IN SURGERY. - ISSN 2038-131X. - ELETTRONICO. - 75:2(2023), pp. 403-408. [10.1007/s13304-022-01422-2]

Frail patients dropping out of neoadjuvant treatment: what should we do?

Monti, Manlio;Solaini, Leonardo;Ercolani, Giorgio
2023

Abstract

Perioperative oncological treatment is currently the gold standard approach in Europe for Advanced Gastric Cancer patients. Unfortunately, patients dropping out due to worsening conditions has been frequently observed, but these data are seldomly considered and reported. To analyze frequency and propose solutions to support these patients, we reconsidered our results from the GASTRODOC randomized trial performed by [blinded for reviewers] and GIRCG on 91 patients. Thirty-four patients (37.4%) suspended chemotherapy and five (5.4%) did not reach surgery. Ten patients (11%) presented unacceptable toxicity related to gastrointestinal symptoms, six ended the treatment for investigator decision and six for progression, five patients withdrew their consent, five patients were excluded because of surgical complications and long hospitalization, and two patients died. Even though not significant, survival rates for patients who interrupted treatment in the whole trial were lower (5-year OS completed 64.6 vs. interrupted 41.8 p 0.07). Promptness in giving patient support for gastrointestinal symptoms, careful evaluation of anemia and patient nutritional status, and psychological programs from the beginning of the oncologic treatment may improve the final results.
2023
Frail patients dropping out of neoadjuvant treatment: what should we do? / Morgagni, Paolo; Monti, Manlio; Solaini, Leonardo; Foca, Flavia; Ercolani, Giorgio. - In: UPDATES IN SURGERY. - ISSN 2038-131X. - ELETTRONICO. - 75:2(2023), pp. 403-408. [10.1007/s13304-022-01422-2]
Morgagni, Paolo; Monti, Manlio; Solaini, Leonardo; Foca, Flavia; Ercolani, Giorgio
File in questo prodotto:
File Dimensione Formato  
s13304-022-01422-2.pdf

accesso riservato

Tipo: Versione (PDF) editoriale
Licenza: Licenza per accesso riservato
Dimensione 460.83 kB
Formato Adobe PDF
460.83 kB Adobe PDF   Visualizza/Apri   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/913037
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact